FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203445105> ?p ?o ?g. }

• W3203445105 endingPage "727" @default.
• W3203445105 startingPage "710" @default.
• W3203445105 abstract "Pulmonary vascular microthrombi are a proposed mechanism of COVID-19 respiratory failure. We hypothesized that early administration of tissue plasminogen activator (tPA) followed by therapeutic heparin would improve pulmonary function in these patients.Does tPA improve pulmonary function in severe COVID-19 respiratory failure, and is it safe?Adults with COVID-19-induced respiratory failure were randomized from May14, 2020 through March 3, 2021, in two phases. Phase 1 (n = 36) comprised a control group (standard-of-care treatment) vs a tPA bolus (50-mg tPA IV bolus followed by 7 days of heparin; goal activated partial thromboplastin time [aPTT], 60-80 s) group. Phase 2 (n = 14) comprised a control group vs a tPA drip (50-mg tPA IV bolus, followed by tPA drip 2 mg/h plus heparin 500 units/h over 24 h, then heparin to maintain aPTT of 60-80 s for 7 days) group. Patients were excluded from enrollment if they had not undergone a neurologic examination or cross-sectional brain imaging within the previous 4.5 h to rule out stroke and potential for hemorrhagic conversion. The primary outcome was Pao2 to Fio2 ratio improvement from baseline at 48 h after randomization. Secondary outcomes included Pao2 to Fio2 ratio improvement of > 50% or Pao2 to Fio2 ratio of ≥ 200 at 48 h (composite outcome), ventilator-free days (VFD), and mortality.Fifty patients were randomized: 17 in the control group and 19 in the tPA bolus group in phase 1 and eight in the control group and six in the tPA drip group in phase 2. No severe bleeding events occurred. In the tPA bolus group, the Pao2 to Fio2 ratio values were significantly (P < .017) higher than baseline at 6 through 168 h after randomization; the control group showed no significant improvements. Among patients receiving a tPA bolus, the percent change of Pao2 to Fio2 ratio at 48 h (16.9% control [interquartile range (IQR), -8.3% to 36.8%] vs 29.8% tPA bolus [IQR, 4.5%-88.7%]; P = .11), the composite outcome (11.8% vs 47.4%; P = .03), VFD (0.0 [IQR, 0.0-9.0] vs 12.0 [IQR, 0.0-19.0]; P = .11), and in-hospital mortality (41.2% vs 21.1%; P = .19) did not reach statistically significant differences when compared with those of control participants. The patients who received a tPA drip did not experience benefit.The combination of tPA bolus plus heparin is safe in severe COVID-19 respiratory failure. A phase 3 study is warranted given the improvements in oxygenation and promising observations in VFD and mortality.ClinicalTrials.gov; No.: NCT04357730; URL: www.gov." @default.
• W3203445105 created "2021-10-11" @default.
• W3203445105 creator A5000531783 @default.
• W3203445105 creator A5001473914 @default.
• W3203445105 creator A5002110221 @default.
• W3203445105 creator A5004129484 @default.
• W3203445105 creator A5004168407 @default.
• W3203445105 creator A5004607212 @default.
• W3203445105 creator A5005772903 @default.
• W3203445105 creator A5008309858 @default.
• W3203445105 creator A5008748881 @default.
• W3203445105 creator A5010401935 @default.
• W3203445105 creator A5013811550 @default.
• W3203445105 creator A5021180522 @default.
• W3203445105 creator A5023794092 @default.
• W3203445105 creator A5027054436 @default.
• W3203445105 creator A5029296416 @default.
• W3203445105 creator A5035762546 @default.
• W3203445105 creator A5039393413 @default.
• W3203445105 creator A5041612225 @default.
• W3203445105 creator A5046797785 @default.
• W3203445105 creator A5047220481 @default.
• W3203445105 creator A5048394100 @default.
• W3203445105 creator A5053060988 @default.
• W3203445105 creator A5054390854 @default.
• W3203445105 creator A5054611268 @default.
• W3203445105 creator A5057600594 @default.
• W3203445105 creator A5062107602 @default.
• W3203445105 creator A5070783673 @default.
• W3203445105 creator A5073615852 @default.
• W3203445105 creator A5073632652 @default.
• W3203445105 creator A5076722307 @default.
• W3203445105 creator A5078445016 @default.
• W3203445105 creator A5081844519 @default.
• W3203445105 creator A5083870849 @default.
• W3203445105 creator A5085083672 @default.
• W3203445105 creator A5085494338 @default.
• W3203445105 creator A5086573408 @default.
• W3203445105 creator A5086579307 @default.
• W3203445105 creator A5087913811 @default.
• W3203445105 creator A5090635720 @default.
• W3203445105 date "2022-03-01" @default.
• W3203445105 modified "2023-10-17" @default.
• W3203445105 title "Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19" @default.
• W3203445105 cites W1978960863 @default.
• W3203445105 cites W1981332109 @default.
• W3203445105 cites W1984486655 @default.
• W3203445105 cites W2035126508 @default.
• W3203445105 cites W2117884155 @default.
• W3203445105 cites W2283987856 @default.
• W3203445105 cites W2399350070 @default.
• W3203445105 cites W3011092057 @default.
• W3203445105 cites W3013176450 @default.
• W3203445105 cites W3014627815 @default.
• W3203445105 cites W3015631662 @default.
• W3203445105 cites W3016327048 @default.
• W3203445105 cites W3016538780 @default.
• W3203445105 cites W3016965546 @default.
• W3203445105 cites W3017725346 @default.
• W3203445105 cites W3024025162 @default.
• W3203445105 cites W3024186531 @default.
• W3203445105 cites W3024270855 @default.
• W3203445105 cites W3027228359 @default.
• W3203445105 cites W3031456278 @default.
• W3203445105 cites W3036625914 @default.
• W3203445105 cites W3041425397 @default.
• W3203445105 cites W3089368825 @default.
• W3203445105 cites W3092457819 @default.
• W3203445105 cites W3118810601 @default.
• W3203445105 cites W3126061642 @default.
• W3203445105 cites W4205922819 @default.
• W3203445105 cites W4213291736 @default.
• W3203445105 cites W4231969161 @default.
• W3203445105 doi "https://doi.org/10.1016/j.chest.2021.09.024" @default.
• W3203445105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8474873" @default.
• W3203445105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34592318" @default.
• W3203445105 hasPublicationYear "2022" @default.
• W3203445105 type Work @default.
• W3203445105 sameAs 3203445105 @default.
• W3203445105 citedByCount "32" @default.
• W3203445105 countsByYear W32034451052022 @default.
• W3203445105 countsByYear W32034451052023 @default.
• W3203445105 crossrefType "journal-article" @default.
• W3203445105 hasAuthorship W3203445105A5000531783 @default.
• W3203445105 hasAuthorship W3203445105A5001473914 @default.
• W3203445105 hasAuthorship W3203445105A5002110221 @default.
• W3203445105 hasAuthorship W3203445105A5004129484 @default.
• W3203445105 hasAuthorship W3203445105A5004168407 @default.
• W3203445105 hasAuthorship W3203445105A5004607212 @default.
• W3203445105 hasAuthorship W3203445105A5005772903 @default.
• W3203445105 hasAuthorship W3203445105A5008309858 @default.
• W3203445105 hasAuthorship W3203445105A5008748881 @default.
• W3203445105 hasAuthorship W3203445105A5010401935 @default.
• W3203445105 hasAuthorship W3203445105A5013811550 @default.
• W3203445105 hasAuthorship W3203445105A5021180522 @default.
• W3203445105 hasAuthorship W3203445105A5023794092 @default.
• W3203445105 hasAuthorship W3203445105A5027054436 @default.
• W3203445105 hasAuthorship W3203445105A5029296416 @default.

• next